{"BSX": {"Ticker": "BSX", "Company": "Boston Scientific", "Sector": "Health Care", "Updated": "2022-04-13", "Rating": [{"Date": "2022-04-13", "Rating": "Resumed", "Organization": "Truist", "Rating_Change": "Buy", "Target_Change": "$52"}, {"Date": "2022-03-02", "Rating": "Resumed", "Organization": "BofA Securities", "Rating_Change": "Buy", "Target_Change": "$55"}], "Score": 2.0, "Cumulative_Rating": "Significant Outperform", "Number_of_Analysts": 2, "Period": "180 days", "Analists": ["Truist", "BofA Securities"], "Price_Target": 53.5}, "KMX": {"Ticker": "KMX", "Company": "CarMax", "Sector": "Consumer Discretionary", "Updated": "2022-04-13", "Rating": [{"Date": "2022-04-13", "Rating": "Downgrade", "Organization": "JP Morgan", "Rating_Change": "Overweight to Neutral", "Target_Change": "$130 to $110"}, {"Date": "2022-04-06", "Rating": "Downgrade", "Organization": "BofA Securities", "Rating_Change": "Buy to Neutral", "Target_Change": "$195 to $165"}, {"Date": "2022-02-16", "Rating": "Downgrade", "Organization": "Evercore ISI", "Rating_Change": "Outperform to In-line", "Target_Change": "$120"}, {"Date": "2022-01-28", "Rating": "Resumed", "Organization": "RBC Capital Mkts", "Rating_Change": "Outperform", "Target_Change": "$157 to $140"}, {"Date": "2022-01-27", "Rating": "Upgrade", "Organization": "Seaport Research Partners", "Rating_Change": "Neutral to Buy", "Target_Change": "$140"}], "Score": -0.2, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 5, "Period": "180 days", "Analists": ["JP Morgan", "Seaport Research Partners", "BofA Securities", "RBC Capital Mkts", "Evercore ISI"], "Price_Target": 135.0}, "EW": {"Ticker": "EW", "Company": "Edwards Lifesciences", "Sector": "Health Care", "Updated": "2022-04-13", "Rating": [{"Date": "2022-04-13", "Rating": "Initiated", "Organization": "Truist", "Rating_Change": "Buy", "Target_Change": "$145"}, {"Date": "2022-04-06", "Rating": "Initiated", "Organization": "Wolfe Research", "Rating_Change": "Outperform", "Target_Change": "$134"}, {"Date": "2022-03-16", "Rating": "Upgrade", "Organization": "Bernstein", "Rating_Change": "Mkt Perform to Outperform", "Target_Change": "$132 to $135"}, {"Date": "2022-03-02", "Rating": "Resumed", "Organization": "BofA Securities", "Rating_Change": "Neutral", "Target_Change": "$130"}, {"Date": "2022-02-02", "Rating": "Upgrade", "Organization": "UBS", "Rating_Change": "Neutral to Buy", "Target_Change": "$121 to $126"}, {"Date": "2022-01-27", "Rating": "Reiterated", "Organization": "UBS", "Rating_Change": "Neutral", "Target_Change": "$125 to $121"}, {"Date": "2022-01-27", "Rating": "Reiterated", "Organization": "Stifel", "Rating_Change": "Buy", "Target_Change": "$132 to $120"}, {"Date": "2022-01-27", "Rating": "Reiterated", "Organization": "Raymond James", "Rating_Change": "Outperform", "Target_Change": "$134 to $126"}, {"Date": "2022-01-27", "Rating": "Reiterated", "Organization": "Evercore ISI", "Rating_Change": "Outperform", "Target_Change": "$130 to $122"}, {"Date": "2022-01-27", "Rating": "Reiterated", "Organization": "Citigroup", "Rating_Change": "Buy", "Target_Change": "$142 to $138"}], "Score": 1.6, "Cumulative_Rating": "Significant Outperform", "Number_of_Analysts": 10, "Period": "180 days", "Analists": ["Raymond James", "UBS", "BofA Securities", "Citigroup", "Bernstein", "Stifel", "Truist", "Evercore ISI", "Wolfe Research"], "Price_Target": 129.7}, "HUM": {"Ticker": "HUM", "Company": "Humana", "Sector": "Health Care", "Updated": "2022-04-13", "Rating": [{"Date": "2022-04-13", "Rating": "Upgrade", "Organization": "UBS", "Rating_Change": "Neutral to Buy", "Target_Change": "$486 to $520"}], "Score": 2.0, "Cumulative_Rating": "Significant Outperform", "Number_of_Analysts": 1, "Period": "180 days", "Analists": ["UBS"], "Price_Target": 520.0}, "ISRG": {"Ticker": "ISRG", "Company": "Intuitive Surgical", "Sector": "Health Care", "Updated": "2022-04-13", "Rating": [{"Date": "2022-04-13", "Rating": "Initiated", "Organization": "Truist", "Rating_Change": "Buy", "Target_Change": "$360"}, {"Date": "2022-04-06", "Rating": "Initiated", "Organization": "Wolfe Research", "Rating_Change": "Peer Perform", "Target_Change": "$315"}, {"Date": "2022-03-25", "Rating": "Initiated", "Organization": "RBC Capital Mkts", "Rating_Change": "Outperform", "Target_Change": "$340"}, {"Date": "2022-03-02", "Rating": "Resumed", "Organization": "BofA Securities", "Rating_Change": "Buy", "Target_Change": "$340"}, {"Date": "2022-02-02", "Rating": "Upgrade", "Organization": "UBS", "Rating_Change": "Neutral to Buy", "Target_Change": "$317 to $325"}, {"Date": "2022-01-31", "Rating": "Upgrade", "Organization": "Piper Sandler", "Rating_Change": "Neutral to Overweight", "Target_Change": "$300 to $310"}, {"Date": "2022-01-25", "Rating": "Downgrade", "Organization": "Redburn", "Rating_Change": "Buy to Neutral", "Target_Change": ""}, {"Date": "2022-01-21", "Rating": "Upgrade", "Organization": "Citigroup", "Rating_Change": "Neutral to Buy", "Target_Change": "$370 to $360"}, {"Date": "2022-01-21", "Rating": "Reiterated", "Organization": "Wells Fargo", "Rating_Change": "Overweight", "Target_Change": "$381 to $350"}, {"Date": "2022-01-21", "Rating": "Reiterated", "Organization": "UBS", "Rating_Change": "Neutral", "Target_Change": "$338 to $317"}, {"Date": "2022-01-21", "Rating": "Reiterated", "Organization": "Stifel", "Rating_Change": "Buy", "Target_Change": "$370 to $325"}, {"Date": "2022-01-21", "Rating": "Reiterated", "Organization": "Robert W. Baird", "Rating_Change": "Outperform", "Target_Change": "$370 to $315"}, {"Date": "2022-01-21", "Rating": "Reiterated", "Organization": "Raymond James", "Rating_Change": "Outperform", "Target_Change": "$383 to $334"}, {"Date": "2022-01-21", "Rating": "Reiterated", "Organization": "Piper Sandler", "Rating_Change": "Neutral", "Target_Change": "$330 to $300"}, {"Date": "2022-01-21", "Rating": "Reiterated", "Organization": "Morgan Stanley", "Rating_Change": "Equal-Weight", "Target_Change": "$375 to $325"}, {"Date": "2022-01-21", "Rating": "Reiterated", "Organization": "Evercore ISI", "Rating_Change": "In-line", "Target_Change": "$340 to $290"}, {"Date": "2022-01-21", "Rating": "Reiterated", "Organization": "Deutsche Bank", "Rating_Change": "Hold", "Target_Change": "$323 to $300"}, {"Date": "2022-01-21", "Rating": "Reiterated", "Organization": "BTIG Research", "Rating_Change": "Buy", "Target_Change": "$372 to $360"}], "Score": 1.17, "Cumulative_Rating": "Outperform", "Number_of_Analysts": 18, "Period": "180 days", "Analists": ["Raymond James", "Robert W. Baird", "Piper Sandler", "UBS", "Morgan Stanley", "Deutsche Bank", "BTIG Research", "BofA Securities", "Redburn", "Citigroup", "Evercore ISI", "Stifel", "Truist", "RBC Capital Mkts", "Wells Fargo", "Wolfe Research"], "Price_Target": 308.22}, "JBHT": {"Ticker": "JBHT", "Company": "J. B. Hunt", "Sector": "Industrials", "Updated": "2022-04-13", "Rating": [{"Date": "2022-04-13", "Rating": "Upgrade", "Organization": "Deutsche Bank", "Rating_Change": "Hold to Buy", "Target_Change": "$210 to $230"}, {"Date": "2022-03-09", "Rating": "Upgrade", "Organization": "Goldman", "Rating_Change": "Neutral to Buy", "Target_Change": "$209 to $231"}, {"Date": "2022-03-02", "Rating": "Upgrade", "Organization": "Vertical Research", "Rating_Change": "Hold to Buy", "Target_Change": ""}, {"Date": "2022-02-18", "Rating": "Upgrade", "Organization": "JP Morgan", "Rating_Change": "Underweight to Neutral", "Target_Change": "$175 to $203"}, {"Date": "2022-01-26", "Rating": "Upgrade", "Organization": "Barclays", "Rating_Change": "Equal Weight to Overweight", "Target_Change": "$220 to $235"}], "Score": 1.2, "Cumulative_Rating": "Outperform", "Number_of_Analysts": 5, "Period": "180 days", "Analists": ["Vertical Research", "JP Morgan", "Goldman", "Deutsche Bank", "Barclays"], "Price_Target": 178.8}, "MDT": {"Ticker": "MDT", "Company": "Medtronic", "Sector": "Health Care", "Updated": "2022-04-13", "Rating": [{"Date": "2022-04-13", "Rating": "Downgrade", "Organization": "Truist", "Rating_Change": "Buy to Hold", "Target_Change": "$124 to $121"}, {"Date": "2022-03-02", "Rating": "Resumed", "Organization": "BofA Securities", "Rating_Change": "Buy", "Target_Change": "$135"}], "Score": 0.5, "Cumulative_Rating": "Outperform", "Number_of_Analysts": 2, "Period": "180 days", "Analists": ["Truist", "BofA Securities"], "Price_Target": 128.0}, "NVDA": {"Ticker": "NVDA", "Company": "Nvidia", "Sector": "Information Technology", "Updated": "2022-04-13", "Rating": [{"Date": "2022-04-13", "Rating": "Upgrade", "Organization": "New Street", "Rating_Change": "Neutral to Buy", "Target_Change": "$280"}, {"Date": "2022-04-11", "Rating": "Downgrade", "Organization": "Robert W. Baird", "Rating_Change": "Outperform to Neutral", "Target_Change": "$360 to $225"}, {"Date": "2022-03-15", "Rating": "Reiterated", "Organization": "Cowen", "Rating_Change": "Outperform", "Target_Change": "$350"}, {"Date": "2022-03-07", "Rating": "Resumed", "Organization": "Goldman", "Rating_Change": "Neutral", "Target_Change": "$245"}, {"Date": "2022-02-17", "Rating": "Downgrade", "Organization": "Summit Insights", "Rating_Change": "Buy to Hold", "Target_Change": ""}], "Score": 0.2, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 5, "Period": "180 days", "Analists": ["Robert W. Baird", "Cowen", "Summit Insights", "Goldman", "New Street"], "Price_Target": 219.0}, "SYK": {"Ticker": "SYK", "Company": "Stryker Corporation", "Sector": "Health Care", "Updated": "2022-04-13", "Rating": [{"Date": "2022-04-13", "Rating": "Initiated", "Organization": "Truist", "Rating_Change": "Hold", "Target_Change": "$296"}, {"Date": "2022-03-16", "Rating": "Upgrade", "Organization": "Bernstein", "Rating_Change": "Mkt Perform to Outperform", "Target_Change": "$288 to $295"}, {"Date": "2022-03-15", "Rating": "Resumed", "Organization": "Evercore ISI", "Rating_Change": "Outperform", "Target_Change": "$284"}, {"Date": "2022-03-02", "Rating": "Resumed", "Organization": "BofA Securities", "Rating_Change": "Buy", "Target_Change": "$300"}], "Score": 1.5, "Cumulative_Rating": "Significant Outperform", "Number_of_Analysts": 4, "Period": "180 days", "Analists": ["Truist", "Bernstein", "Evercore ISI", "BofA Securities"], "Price_Target": 293.75}, "TFX": {"Ticker": "TFX", "Company": "Teleflex", "Sector": "Health Care", "Updated": "2022-04-13", "Rating": [{"Date": "2022-04-13", "Rating": "Initiated", "Organization": "Truist", "Rating_Change": "Hold", "Target_Change": "$370"}], "Score": 0.0, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 1, "Period": "180 days", "Analists": ["Truist"], "Price_Target": 370.0}, "ZBH": {"Ticker": "ZBH", "Company": "Zimmer Biomet", "Sector": "Health Care", "Updated": "2022-04-13", "Rating": [{"Date": "2022-04-13", "Rating": "Downgrade", "Organization": "Truist", "Rating_Change": "Buy to Hold", "Target_Change": "$128 to $142"}, {"Date": "2022-04-01", "Rating": "Downgrade", "Organization": "Citigroup", "Rating_Change": "Buy to Neutral", "Target_Change": "$125.15 to $135"}, {"Date": "2022-03-02", "Rating": "Resumed", "Organization": "BofA Securities", "Rating_Change": "Underperform", "Target_Change": "$120"}, {"Date": "2022-03-02", "Rating": "Downgrade", "Organization": "Loop Capital", "Rating_Change": "Buy to Hold", "Target_Change": "$130"}, {"Date": "2022-02-08", "Rating": "Reiterated", "Organization": "Wells Fargo", "Rating_Change": "Underweight", "Target_Change": "$124 to $111"}, {"Date": "2022-02-08", "Rating": "Reiterated", "Organization": "UBS", "Rating_Change": "Neutral", "Target_Change": "$130 to $121"}, {"Date": "2022-02-08", "Rating": "Reiterated", "Organization": "Truist", "Rating_Change": "Buy", "Target_Change": "$145 to $128"}, {"Date": "2022-02-08", "Rating": "Reiterated", "Organization": "Stifel", "Rating_Change": "Buy", "Target_Change": "$178 to $130"}, {"Date": "2022-02-08", "Rating": "Reiterated", "Organization": "RBC Capital Mkts", "Rating_Change": "Sector Perform", "Target_Change": "$140 to $125"}, {"Date": "2022-02-08", "Rating": "Reiterated", "Organization": "JP Morgan", "Rating_Change": "Neutral", "Target_Change": "$150 to $114"}, {"Date": "2022-02-08", "Rating": "Reiterated", "Organization": "JMP Securities", "Rating_Change": "Mkt Outperform", "Target_Change": "$175 to $145"}, {"Date": "2022-02-08", "Rating": "Reiterated", "Organization": "Deutsche Bank", "Rating_Change": "Hold", "Target_Change": "$140 to $121"}, {"Date": "2022-02-08", "Rating": "Reiterated", "Organization": "Citigroup", "Rating_Change": "Buy", "Target_Change": "$150 to $129"}, {"Date": "2022-02-08", "Rating": "Downgrade", "Organization": "Canaccord Genuity", "Rating_Change": "Buy to Hold", "Target_Change": "$165 to $125"}, {"Date": "2022-02-02", "Rating": "Downgrade", "Organization": "UBS", "Rating_Change": "Buy to Neutral", "Target_Change": "$172 to $130"}, {"Date": "2022-01-19", "Rating": "Downgrade", "Organization": "Wells Fargo", "Rating_Change": "Equal Weight to Underweight", "Target_Change": "$170 to $124"}], "Score": -0.06, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 16, "Period": "180 days", "Analists": ["Canaccord Genuity", "JP Morgan", "UBS", "JMP Securities", "Deutsche Bank", "BofA Securities", "Citigroup", "Stifel", "Loop Capital", "Truist", "RBC Capital Mkts", "Wells Fargo"], "Price_Target": 126.88}}